A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy
Latest Information Update: 28 Jun 2023
At a glance
- Drugs Odetiglucan (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors HiberCell
- 19 Jun 2023 Status changed from active, no longer recruiting to completed.
- 20 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology